Jabodon PT Co. Buys Shares of 121,158 Horizon Pharma PLC (HZNP)

Jabodon PT Co. bought a new stake in Horizon Pharma PLC (NASDAQ:HZNP) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 121,158 shares of the biopharmaceutical company’s stock, valued at approximately $2,372,000. Horizon Pharma comprises about 3.1% of Jabodon PT Co.’s holdings, making the stock its 12th largest position.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. First Quadrant L P CA boosted its stake in Horizon Pharma by 189.1% during the 3rd quarter. First Quadrant L P CA now owns 6,117 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 4,001 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Horizon Pharma by 74.4% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,091 shares of the biopharmaceutical company’s stock worth $128,000 after acquiring an additional 3,877 shares during the period. Quantitative Systematic Strategies LLC acquired a new stake in shares of Horizon Pharma in the 2nd quarter worth $172,000. Strs Ohio lifted its stake in shares of Horizon Pharma by 74.2% in the 2nd quarter. Strs Ohio now owns 10,800 shares of the biopharmaceutical company’s stock worth $178,000 after acquiring an additional 4,600 shares during the period. Finally, Inspirion Wealth Advisors LLC acquired a new stake in shares of Horizon Pharma in the 2nd quarter worth $207,000. 87.24% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ HZNP opened at $19.35 on Wednesday. The company has a quick ratio of 1.63, a current ratio of 1.70 and a debt-to-equity ratio of 2.19. Horizon Pharma PLC has a 52 week low of $12.55 and a 52 week high of $21.25. The stock has a market capitalization of $3.22 billion, a P/E ratio of 16.40, a P/E/G ratio of 1.22 and a beta of 1.29.

Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported $0.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.17. Horizon Pharma had a negative net margin of 28.02% and a positive return on equity of 19.05%. The firm had revenue of $302.84 million during the quarter, compared to analysts’ expectations of $275.51 million. During the same quarter last year, the business earned $0.41 earnings per share. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. As a group, research analysts anticipate that Horizon Pharma PLC will post 1.34 EPS for the current fiscal year.

In related news, EVP Geoffrey M. Curtis sold 9,904 shares of the firm’s stock in a transaction dated Thursday, August 16th. The shares were sold at an average price of $20.63, for a total value of $204,319.52. Following the completion of the sale, the executive vice president now owns 28,767 shares in the company, valued at $593,463.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.90% of the stock is owned by company insiders.

Several research firms have recently commented on HZNP. TheStreet upgraded shares of Horizon Pharma from a “d+” rating to a “c” rating in a research note on Wednesday, October 31st. Cantor Fitzgerald raised their target price on shares of Horizon Pharma to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 25th. BidaskClub cut shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, September 26th. Morgan Stanley raised their target price on shares of Horizon Pharma from $16.00 to $24.00 and gave the stock an “equal weight” rating in a research note on Friday, August 17th. Finally, JMP Securities set a $22.00 target price on shares of Horizon Pharma and gave the stock a “buy” rating in a research note on Saturday, October 6th. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $23.00.

WARNING: “Jabodon PT Co. Buys Shares of 121,158 Horizon Pharma PLC (HZNP)” was first published by WKRB News and is the property of of WKRB News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.wkrb13.com/2018/11/07/jabodon-pt-co-buys-shares-of-121158-horizon-pharma-plc-hznp.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

Featured Article: Determine Your Level of Risk Tolerance

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply